Kymera Therapeutics, Inc. financial data

Symbol
KYMR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
500 North Beacon Street, 4 Th Floor, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 848 % +42.6%
Debt-to-equity 18.6 % -50.5%
Return On Equity -28.7 % +17.7%
Return On Assets -24.2 % +4.51%
Operating Margin -556 % -164%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.9M shares +5.84%
Common Stock, Shares, Outstanding 64.9M shares +16.7%
Entity Public Float 1.15B USD +13.2%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 75M shares +28.6%
Weighted Average Number of Shares Outstanding, Diluted 75M shares +28.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 47.1M USD -40.1%
Research and Development Expense 240M USD +27.1%
General and Administrative Expense 63.5M USD +15.4%
Operating Income (Loss) -262M USD -58.1%
Income Tax Expense (Benefit) 200K USD
Net Income (Loss) Attributable to Parent -224M USD -52.3%
Earnings Per Share, Basic -2.98 USD/shares -18.3%
Earnings Per Share, Diluted -2.98 USD/shares -18.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 120M USD +9.36%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 510M USD +25.9%
Property, Plant and Equipment, Net 50.5M USD +4.83%
Operating Lease, Right-of-Use Asset 47.4M USD -10.5%
Other Assets, Noncurrent 1.95M USD -7.93%
Assets 978M USD +69.9%
Accounts Payable, Current 5.99M USD -15.4%
Accrued Liabilities, Current 34.9M USD +2.96%
Contract with Customer, Liability, Current 13.6M USD -64.2%
Liabilities, Current 67.8M USD -20.9%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 72.4M USD -5.98%
Other Liabilities, Noncurrent 0 USD
Liabilities 142M USD -21.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.49M USD -169%
Retained Earnings (Accumulated Deficit) -755M USD -42.2%
Stockholders' Equity Attributable to Parent 836M USD +112%
Liabilities and Equity 978M USD +69.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.6M USD +9.96%
Net Cash Provided by (Used in) Financing Activities 354M USD +30423%
Net Cash Provided by (Used in) Investing Activities -331M USD -1445%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 64.9M shares +16.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.4M USD +9.78%
Interest Paid, Excluding Capitalized Interest, Operating Activities 49K USD -5.77%
Deferred Tax Assets, Valuation Allowance 236M USD +45.5%
Deferred Tax Assets, Gross 260M USD +41.1%
Operating Lease, Liability 84M USD +2.34%
Depreciation 7.4M USD +106%
Payments to Acquire Property, Plant, and Equipment 7.4M USD +84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -225M USD -57.7%
Lessee, Operating Lease, Liability, to be Paid 125M USD -4.22%
Property, Plant and Equipment, Gross 66.5M USD +13.6%
Operating Lease, Liability, Current 11.6M USD +129%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.4M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.1M USD +119%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 40.9M USD -15.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.8M USD +3%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 13.2M USD +3%
Depreciation, Depletion and Amortization 1.46M USD +66.2%
Deferred Tax Assets, Net of Valuation Allowance 23.6M USD +8.54%
Share-based Payment Arrangement, Expense 55M USD +27.6%